Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is ...

Leerink upgraded Doximity (DOCS) to Outperform from Market Perform with a price target of $90, up from $60. While “admittedly late on this,” ...

Equities researchers at Leerink Partnrs boosted their Q2 2025 earnings estimates for shares of Twist Bioscience in a research ...

Fintel reports that on February 6, 2025, Leerink Partners downgraded their outlook for Hologic (NasdaqGS:HOLX) from Outperform to Market Perform. Analyst Price Forecast Suggests 20.21% Upside As of ...

The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves the ...

Leerink downgraded Hologic (HOLX) to Market Perform from Outperform with a price target of $75, down from $80, following the fiscal Q1 report.

Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...

Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of AbbVie in a research note issued to investors on Monday, February 3rd. Leerink ...

With a volume of 12,212,671, the price of MRK is down -1.44% at $88.38. RSI indicators hint that the underlying stock may be ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

Q4 2024 . Management View. Labcorp reported revenue of $3.3 billion for Q4 2024, an increase of 10% year-over-year, with Di ...